Author: Pharmaceutical Scientist

FDA Issues Landmark Biosimilar Guidance Incorporating Regulatory Reforms Advised by Professor Niazi: Further Cutting Development Costs by Up to 50%

March 10, 2026
Professor Sarfaraz Niazi’s Scientific Framework Adopted as FDA Modernizes Clinical Trial Evaluation Through Bayesian Methods

January 20, 2026

FDA Issues Landmark Biosimilar Guidance Incorporating Regulatory Reforms Advised by Professor Niazi: Further Cutting Development Costs by Up to 50%